STERIS plc provided revenue guidance for fiscal 2023. For fiscal 2023, constant currency organic revenue growth is now anticipated to be approximately 10%, compared with prior expectations of 11%, reflecting ongoing supply chain challenges and procedure volumes somewhat lighter than anticipated. As reported revenue is expected to increase approximately 9%, reflecting the net impact of acquisitions and divestitures as well as approximately $100 million in anticipated negative impact of foreign currency fluctuations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
228.5 USD | +0.06% | -0.29% | +3.93% |
05-20 | Steris Insider Sold Shares Worth $267,313, According to a Recent SEC Filing | MT |
05-17 | Steris Insider Sold Shares Worth $7,532,366, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.93% | 22.59B | |
-6.03% | 179B | |
+1.08% | 108B | |
-2.19% | 69.03B | |
-5.98% | 45.83B | |
+12.31% | 45.39B | |
+8.60% | 43.17B | |
+15.98% | 29.89B | |
+13.65% | 25.49B | |
-9.57% | 23.95B |
- Stock Market
- Equities
- STE Stock
- News STERIS plc
- STERIS plc Provides Revenue Guidance for Fiscal 2023